Experimental Vaccines

Pfizer’s Booster Bonanza: A Never-Ending Jabfest

Let me tell you, folks, the world of mRNA vaccines just got a whole lot weirder—and the “science” isn’t holding back. Harukazu Hirano and Hiroshi Asada, straight out of Japan’s health research labs, unleashed a Pandora’s box of studies on what happens after multiple rounds of Pfizer’s BNT162b2 boosters. You think the immune system is thriving after shot number four or five? Think again.

The Good, the Bad, and the Boosted

The research claims booster doses “enhance” immunity, especially for older adults who are, let’s be real, Pfizer’s cash cow. Sure, antibody levels spike after each jab—bravo, Big Pharma. But wait. Antibodies start plummeting within six months, leaving us right back where we started. What’s the plan? A booster for your booster? And another one?

These scientists also praised T-cell responses for holding the line. But let’s ask the real question: If boosters are so great, why does the immunity fade so fast? Is this planned obsolescence for the immune system, a Big Pharma dream turned dystopian reality? You bet it is.

Bivalent Boosters: A Marketing Gimmick?

Enter the so-called “bivalent boosters” designed to tackle Omicron. They claim to protect against new variants, but here’s the kicker: immunity from these miracle shots also fades. It’s like a revolving door of dependency—get a jab, feel safe for a few months, and then—bam!—back in line for another dose. Is it protection or just profit wrapped in a syringe?

Mix-and-Match Madness

Let’s talk heterologous boosters—fancy talk for mixing vaccines. According to these studies, swapping AstraZeneca for Pfizer allegedly “broadens immune responses.” But let’s not forget the untested waters we’re wading into. Where are the long-term studies? Oh, that’s right—they don’t exist. You, my friend, are the guinea pig.

The Never-Ending Jab Factory

Here’s the bottom line: Pfizer’s boosters are the gift that keeps on giving—to their shareholders. As immunity wanes, the shots keep rolling out. If this isn’t a eugenicist’s dream of perpetual population control, what is? It’s a never-ending cycle of dependency: jab, fade, repeat. And don’t even get me started on the side effects—those are swept under the rug faster than you can say “VAERS.”

This article was written by Dick Vegas, created by Kenny Valenzuela, and powered by experimentalvaccines.org. For more hard-hitting truths, visit https://experimentalvaccines.org

Related research

1. Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55
This study explores the immune responses elicited by a bivalent Omicron-adapted BNT162b2 booster in adults over 55, showing robust protection against emerging variants.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2213082

2. Humoral and Cellular Immune Response in Elderly Residents of Long-Term Care Facilities
Examines the immunogenicity of the BNT162b2 vaccine in elderly residents, highlighting antibody titers and T cell responses.
https://www.mdpi.com/1422-0067/24/18/13728

3. Durability of Immune Response After COVID-19 Booster Vaccination
Assesses the longevity of immune responses following booster doses of the BNT162b2 vaccine in older adults, noting a gradual decline over time.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796277

4. Booster Vaccination with BNT162b2 in Children and Adolescents
Investigates the immune responses of children and adolescents after receiving the BNT162b2 booster, showing enhanced protection.
https://www.mdpi.com/2076-393X/12/8/919

5. Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 (AstraZeneca)
Explores the immune responses elicited by a BNT162b2 booster in individuals previously vaccinated with ChAdOx1.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.859019/full

1. Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55

Conclusion: The bivalent booster effectively enhances immunity against both the original SARS-CoV-2 strain and Omicron BA.1. It shows a robust neutralizing antibody response, especially in individuals with prior exposure to the virus or vaccinations. This adaptation improves coverage against evolving variants.

Implications: Bivalent boosters could help mitigate the impact of emerging variants in older populations.

—

2. Humoral and Cellular Immune Response in Elderly Residents of Long-Term Care Facilities

Conclusion: Elderly residents displayed a significant, though somewhat reduced, immune response to the BNT162b2 vaccine compared to younger individuals. Cellular responses (T-cell activity) were preserved, which is crucial for long-term immunity.

Implications: Regular monitoring and potential booster doses are critical to maintaining immunity in vulnerable elderly populations.

—

3. Durability of Immune Response After COVID-19 Booster Vaccination

Conclusion: Booster doses of the BNT162b2 vaccine significantly increased both humoral (antibody-mediated) and cellular immune responses. However, antibody levels gradually waned over six months, particularly against newer variants like Omicron.

Implications: Booster doses may need to be administered periodically to sustain high levels of protection, especially in older adults.

—

4. Booster Vaccination with BNT162b2 in Children and Adolescents

Conclusion: The BNT162b2 booster significantly improved both antibody titers and cellular immunity in the pediatric population, providing enhanced protection against severe disease and transmission.

Implications: Extending booster programs to children can contribute to broader community immunity and reduce severe outcomes.

—

5. Humoral and Cellular Responses to BNT162b2 as a Booster After ChAdOx1 (AstraZeneca) Doses

Conclusion: The BNT162b2 booster elicited strong immune responses in individuals who previously received two doses of the ChAdOx1 vaccine. This included higher neutralizing antibody levels and robust T-cell responses, which were critical against variants.

Implications: Heterologous booster strategies (mixing vaccine types) are effective and should be considered in vaccination programs.

—

Overall Conclusions Across Studies

1. Booster doses of BNT162b2 are crucial for maintaining robust immune protection, particularly in older adults and high-risk groups.

2. Immune responses wane over time, necessitating periodic boosters to sustain protection, especially against emerging variants like Omicron.

3. Both humoral and cellular immunity are enhanced by booster doses, with preserved T-cell responses being critical for long-term defense.

4. Adapted boosters (e.g., bivalent formulations) demonstrate superior efficacy against specific variants, making them key tools in managing the evolving pandemic.

5. Heterologous (mix-and-match) booster regimens are effective, broadening immune responses in those initially vaccinated with other platforms like ChAdOx1.

• The COVID-19 “After Action Review” filled with Side Effects or simply EFFECTSJanuary 13, 2025
  A House of Cards: How the COVID-19 “After Action Review” Is More Smoke and Mirrors By Dick VegasPaisley Patterns, Truth Bombs, and the Never-Ending Quest for Clarity The Illusion of Accountability The U.S. House of Representatives Select Subcommittee […] ↓ Read the rest of this entry…